The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models-Reference-Cited by-同舟云学术

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Published:2016-10-25 Issue:22 Volume:22 Page:5527-5538
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Zhang Sen,Anjum Rana,Squillace Rachel,Nadworny Sara,Zhou Tianjun,Keats Jeff,Ning Yaoyu,Wardwell Scott D.,Miller David,Song Youngchul,Eichinger Lindsey,Moran Lauren,Huang Wei-Sheng,Liu Shuangying,Zou Dong,Wang Yihan,Mohemmad Qurish,Jang Hyun Gyung,Ye Emily,Narasimhan Narayana,Wang Frank,Miret Juan,Zhu Xiaotian,Clackson Tim,Dalgarno David,Shakespeare William C.,Rivera Victor M.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 273 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a first-in-class protein degrader for the c-ros oncogene 1 (ROS1);Bioorganic Chemistry;2024-09

2. A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy;Current Protein & Peptide Science;2024-09

3. In-silico QSAR Modeling for Identification of Novel Anticancer Agent as;PHYS CHEM RES;2024

4. Cancer-associated fibroblasts confer ALK inhibitor resistance inEML4-ALK-driven lung cancer via concurrent integrin and MET signaling;2024-08-28

5. Distinct Amino Acid-Based PROTACs Target Oncogenic Kinases for Degradation in Non-Small Cell Lung Cancer (NSCLC);Journal of Medicinal Chemistry;2024-08-08